Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2024-03-08 Regulatory Filings
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding the date of a board meeting scheduled to consider and approve the annual results for the year ended December 31, 2023, and the recommendation on the payment of a final dividend. The document is short (1531 characters) and does not contain any financial data or the actual annual report. It is a notice about the upcoming board meeting and the forthcoming annual results publication, not the report itself. According to the 'Menu vs Meal' rule, such announcements are classified as Regulatory Filings (RNS) because they announce the timing of report approval and publication but do not include the report or substantive financial data.
2024-03-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
Transaction in Own Shares Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on changes in issued shares, share repurchases, cancellations, and related confirmations for Simcere Pharmaceutical Group Limited. It references the Hong Kong Exchanges and Clearing Limited and the Exchange Listing Rules Chapter 19B. The document includes specific data on share capital movements, repurchases, cancellations, and share options, but it is not a full financial report, earnings release, or management discussion. It is a regulatory disclosure about share capital changes and repurchases, which fits the category of Transaction in Own Shares (POS) as it reports on the company's repurchase and cancellation of its own shares. The document length and content confirm it is not a brief announcement but a detailed regulatory filing on share transactions. Therefore, the most appropriate classification is POS (Transaction in Own Shares).
2024-03-05 English
DISCLOSEABLE TRANSACTION IN RELATION TO DEEMED DISPOSAL OF EQUITY INTEREST IN SIMCERE ZAIMING
Capital/Financing Update Classification · 95% confidence The document is an announcement by Simcere Pharmaceutical Group Limited regarding a capital contribution transaction involving a deemed disposal of equity interest in a subsidiary, Simcere Zaiming. It details the terms of the capital contribution agreement, parties involved, valuation methodology, and regulatory implications under the Hong Kong Listing Rules. The content focuses on a financing transaction and equity interest changes rather than financial results, management changes, or legal proceedings. It is a detailed disclosure of a capital/financing event, not a full financial report or earnings release. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive transaction disclosure.
2024-02-25 English
VOLUNTARY ANNOUNCEMENT - PUBLICATION BY JAMA NEUROLOGY ABOUT THE PHASE III CLINICAL STUDIES RESULTS OF SANBEXIN SUBLINGUAL TABLETS FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the publication of clinical study results in a medical journal (JAMA Neurology) about their drug Sanbexin[®] sublingual tablets. It provides detailed information about the clinical trial design, results, and drug development status. There is no indication that this is a financial report, regulatory filing, or management discussion. The document is an announcement of a scientific/clinical development rather than a financial or governance report. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a voluntary announcement about business development and clinical study results, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-02-20 English
PROFIT ALERT
Earnings Release Classification · 95% confidence The document is titled 'PROFIT ALERT' and is an announcement by Simcere Pharmaceutical Group Limited regarding preliminary unaudited financial results for the fiscal year ended December 31, 2023. It provides estimated revenue and profit figures, explains reasons for profit changes, and states that the final audited annual results will be published later (expected in late March 2024). The document is relatively short (5247 characters) and serves as an early notification of expected financial performance rather than a full annual report or earnings release. It does not contain full financial statements or detailed analysis, but rather a preliminary profit warning. This fits the profile of a Capital/Financing Update or Earnings Release. However, since it is a profit alert (a type of earnings guidance or preliminary results announcement) and not the final earnings release, the best fit is Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. Therefore, the document should be classified as an Earnings Release (ER).
2024-02-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
Regulatory Filings Classification · 100% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 January 2024. It details movements in issued shares, share options, warrants, convertibles, and other share-related activities for Simcere Pharmaceutical Group Limited. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, focusing on share capital and share movements rather than financial performance or management commentary. It does not contain financial statements or earnings data, nor is it a report or presentation. It is a regulatory filing related to share capital movements and compliance with listing rules. Therefore, it fits best under the category 'Regulatory Filings (RNS)' as a general regulatory announcement that does not fit other specific categories.
2024-02-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.